CompletedNCT05593029
SEP-363856 added to antidepressants for adult depression
About this title
Read the official source — NCT05593029This study evaluated the safety and effectiveness of SEP-363856 for people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SEP-363856 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 76 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 9, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 929
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05593029
- Official title
Show the full official title
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Scottsdale, United States · Tucson, United States
69 more locations
- Bentonville, United States
- Culver City, United States
- Encino, United States
- Garden Grove, United States
- Long Beach, United States
- Orange, United States
- Redlands, United States
- Santee, United States
- Sherman Oaks, United States
- Temecula, United States
- Torrance, United States
- Walnut Creek, United States
- Hartford, United States
- Jacksonville, United States
- Maitland, United States
- Miami, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Snellville, United States
- Chicago, United States
- Warrenville, United States
- Shreveport, United States
- Gaithersburg, United States
- Boston, United States
- Roslindale, United States
- Watertown, United States
- Worcester, United States
- Bloomfield Hills, United States
- Flowood, United States
- Cherry Hill, United States
- Brooklyn, United States
- Inwood, United States
- New York, United States
- Cincinnati, United States
- Columbus, United States
- Oklahoma City, United States
- West Chester, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Fort Worth, United States
- Houston, United States
- Millcreek, United States
- Everett, United States
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Vratsa, Bulgaria
- Chatham, Canada
- Ottawa, Canada
- Toronto, Canada
- Kladno, Czechia
- Ptzen, Czechia
- Klecany, Czechia
- Prague, Czechia
- Wiesbaden, Germany
- Chemnitz, Germany
- Stralsund, Germany
- Schwerin, Germany
- Westerstede, Germany
- Budapest, Hungary
- Poznan, Poland
- Bydgoszcz, Poland
- Bialystok, Poland
- Lublin, Poland
- Szkolkarska 32, Poland
- Czechia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SEP-363856 for people with depression.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-363856.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
